A. Nanduudu

发表

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2016, The lancet. HIV.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

C. Giaquinto, H. Mujuru, D. Gibb, 2020, The lancet. HIV.

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

C. Giaquinto, H. Mujuru, D. Gibb, 2022, The lancet. HIV.

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

C. Giaquinto, N. Klein, T. Bunupuradah, 2018, PloS one.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinic

J. Blackstone, E. Williams, C. Giaquinto, 2023, EClinicalMedicine.

Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub‐study of the ODYSSEY randomized controlled trial

C. Giaquinto, P. Musoke, C. Kityo, 2023, Journal of the International AIDS Society.